Full-Time

Director – Finance and Strategic Modeling

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$210k - $253kAnnually

Expert

San Carlos, CA, USA

Position based out of headquarters in Redwood City, CA.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Requirements
  • Bachelor’s degree and 10+ years of relevant experience in finance, banking, and/or consulting.
  • Advanced excel-based modelling experience.
  • Strong analytical and strategic thinking skills.
  • Excellent written and verbal communication skills.
  • Ability to lead teams and collaborate cross-functionally.
  • Initiative-taking and able to work independently.
  • Resourceful, motivated, and able to identify potential issues or problems and find solutions.
Responsibilities
  • Create and maintain financial models (P&L, Valuation, NPV, DCF) that help guide near and long-term portfolio planning and decision making.
  • Provide finance support and develop financial models to assist in business development and corporate strategy efforts.
  • Assist in maintenance and update of the long-range financial model.
  • Conduct scenario and sensitivity analyses
  • Support and provide financial insights for portfolio planning and prioritization.
  • Deliver clear, articulate analyses and insights to inform decisions for single assets and larger portfolio.
  • Effectively partner with multiple functions to align on key assumptions, including commercial organization for revenue projections and program management for probability of technical and regulatory success (PTRS)
  • Ad-hoc financial analysis support

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?